Last updated on February 2018

A Study to Evaluate the Performance and Safety of CBL-101 Versus Vismed Multi Eye Drops in the Management of Dry Eye

Brief description of study

The primary objectives of this investigation are to show that the performance of CBL-101 Eye Drops is non-inferior to that of Vismed Multi eye drops in subjects with moderate to severe keratoconjunctivitis sicca after 28 days, and to assess the safety of CBL-101 Eye Drops during a 90-day period with treatment administered 3 to 6 times per day.

Detailed Study Description

Study duration will be approximately 15 weeks from screening to the last visit. Subjects will visit the clinic approximately 5 times.

Clinical Study Identifier: NCT02975102

Find a site near you

Start Over